Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Orlance Coccidioides nucleic acid vaccine
- Development stage
- Preclinical
- Lead developer
- Orlance
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Epidermal
01
Overview
Orlance's Coccidioides nucleic acid vaccine is a preclinical prophylactic candidate designed to prevent Valley Fever (coccidioidomycosis), a fungal infection caused by *Coccidioides immitis* or *Coccidioides posadasii*. The vaccine is delivered using the proprietary MACH-1 (Micro-particle Accelerated Cellular High-efficiency) platform, an epidermal powdered gene gun (EPGG). This technology involves coating gold microparticles with DNA plasmids encoding fungal antigens and accelerating them into the epidermal layer of the skin. By delivering the genetic material directly to the skin's immune-rich environment, specifically targeting Langerhans cells and dermal dendritic cells, the vaccine aims to elicit potent cellular and humoral immune responses without the need for traditional needles or cold-chain storage.
- Other names
- Valley Fever DNA vaccineCoccidioidomycosis nucleic acid vaccineMACH-1 Valley Fever vaccineMACH1 Valley Fever vaccineMACH 1 Valley Fever vaccine
Beyond the preview
Go deeper on Orlance Coccidioides nucleic acid vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Orlance Coccidioides nucleic acid vaccine.